Patient demographic and baseline disease characteristics
| Characteristic . | n = 50 . |
|---|---|
| Sex, male/female, n | 28/22 |
| Median age (range), y | 57 (38-65) |
| ECOG PS, n (%) | |
| 0-1 | 47 (94) |
| 2 | 3 (6) |
| ISS stage, n (%) | |
| I | 21 (42) |
| II | 17 (34) |
| III | 12 (24) |
| R-ISS stage, n (%) | |
| II | 38 (76) |
| III | 12 (24) |
| EMD∗ | 4 (9.3) |
| Primary plasma cell leukemia | 3 (6) |
| HR cytogenetic abnormalities, n (%) | 50 (100) |
| del17p, n (%) | 20 (40) |
| t(4;14), n (%) | 26 (52) |
| t(14;16), n (%) | 10 (20) |
| gain1q, n (%) | 25 (50) |
| 1q duplication | 20 (40) |
| 1q amplification | 5 (10) |
| del1p, n (%) | 6 (12) |
| ≥2 HR cytogenetic abnormalities, n (%) | 30 (60) |
| Characteristic . | n = 50 . |
|---|---|
| Sex, male/female, n | 28/22 |
| Median age (range), y | 57 (38-65) |
| ECOG PS, n (%) | |
| 0-1 | 47 (94) |
| 2 | 3 (6) |
| ISS stage, n (%) | |
| I | 21 (42) |
| II | 17 (34) |
| III | 12 (24) |
| R-ISS stage, n (%) | |
| II | 38 (76) |
| III | 12 (24) |
| EMD∗ | 4 (9.3) |
| Primary plasma cell leukemia | 3 (6) |
| HR cytogenetic abnormalities, n (%) | 50 (100) |
| del17p, n (%) | 20 (40) |
| t(4;14), n (%) | 26 (52) |
| t(14;16), n (%) | 10 (20) |
| gain1q, n (%) | 25 (50) |
| 1q duplication | 20 (40) |
| 1q amplification | 5 (10) |
| del1p, n (%) | 6 (12) |
| ≥2 HR cytogenetic abnormalities, n (%) | 30 (60) |
ECOG PS, Eastern Cooperative Oncology Group performance status; EMD, extra-medullary disease; Ig, immunoglobulin; ISS, International Staging System; R-ISS, revised ISS.
∗Assessed in patients with baseline PET-CT (n = 43) (see Figure 1).